用于治疗自身免疫性和炎性疾病的新型酪氨酸激酶2抑制剂
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 May 16;15(6):769-770. doi: 10.1021/acsmedchemlett.4c00196. eCollection 2024 Jun 13.
Abstract
Provided herein are novel tyrosine kinase 2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.
摘要
本文提供了新型酪氨酸激酶2抑制剂、药物组合物、此类化合物在治疗自身免疫性和炎性疾病中的用途，以及制备此类化合物的方法。
相似文献
1
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 May 16;15(6):769-770. doi: 10.1021/acsmedchemlett.4c00196. eCollection 2024 Jun 13.
2
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Jan 26;15(2):177-178. doi: 10.1021/acsmedchemlett.4c00011. eCollection 2024 Feb 8.
3
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
4
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Feb 6;15(3):320-321. doi: 10.1021/acsmedchemlett.4c00024. eCollection 2024 Mar 14.
5
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Feb 14;15(3):322-323. doi: 10.1021/acsmedchemlett.4c00044. eCollection 2024 Mar 14.
6
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Apr 23;15(5):581-582. doi: 10.1021/acsmedchemlett.4c00169. eCollection 2024 May 9.
7
Novel Tetrahydropyrido[3,4-]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.
ACS Med Chem Lett. 2024 Jan 31;15(3):318-319. doi: 10.1021/acsmedchemlett.4c00023. eCollection 2024 Mar 14.
8
Novel Pyrido[3,2-]pyrimidines as HPK1 Inhibitors for Treating Cancer and Inflammatory and Autoimmune Diseases.
ACS Med Chem Lett. 2023 Nov 27;14(12):1627-1628. doi: 10.1021/acsmedchemlett.3c00506. eCollection 2023 Dec 14.
9
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
ACS Med Chem Lett. 2023 Apr 20;14(5):549-550. doi: 10.1021/acsmedchemlett.3c00131. eCollection 2023 May 11.
10
Novel IRAK4 Inhibitors for Treating Asthma, COPD, Cancer, Autoinflammatory Diseases, and Autoimmune Diseases.
ACS Med Chem Lett. 2023 Nov 3;14(12):1617-1618. doi: 10.1021/acsmedchemlett.3c00474. eCollection 2023 Dec 14.
引用本文的文献
1
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
本文引用的文献
1
TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Feb 6;15(3):320-321. doi: 10.1021/acsmedchemlett.4c00024. eCollection 2024 Mar 14.
2
Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.
Int Immunopharmacol. 2024 Jan 5;126:111238. doi: 10.1016/j.intimp.2023.111238. Epub 2023 Nov 20.
3
Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Biomed Pharmacother. 2023 Nov;167:115611. doi: 10.1016/j.biopha.2023.115611. Epub 2023 Sep 29.
4
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets.
MedComm (2020). 2023 Sep 11;4(5):e349. doi: 10.1002/mco2.349. eCollection 2023 Oct.
5
Ubiquitination network in the type I IFN-induced antiviral signaling pathway.
Eur J Immunol. 2023 Sep;53(9):e2350384. doi: 10.1002/eji.202350384. Epub 2023 May 28.
6
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Pharmacol Res. 2023 Mar;189:106642. doi: 10.1016/j.phrs.2022.106642. Epub 2023 Feb 6.
Zotero 插件